ÃÖÁ¾ÆíÁýÀÏ10.29 16:49
°Ë»öÇϱâ
ÀαâmouGEÇÐȸ

[º´¿ø/ÀÇ·á > ÀÇ·á]

±¹¸³¾Ï¼¾ÅÍ °ø¼±¿µ¡¤ÀÌ¿µÁÖ Àü¹®ÀÇ µî, AOS 2022 ´ëÇѾÏÇÐȸ Çмú»ó ¼ö»ó

±è°æÈÆ ±âÀÚ / wkt4619@naver.com
½ÂÀÎ 22-06-22 08:53 | ÃÖÁ¾¼öÁ¤ 22-06-22 09:00  
 

 

 

¡ã¿ÞÂʺÎÅÍ °ø¼±¿µ Àü¹®ÀÇ ,ÀÌ¿µÁÖ Àü¹®ÀÇ, ¼­¹Î¾ÆºÎÀå, ,À¯³²Èñ ¿¬±¸°ú, À¯¿¹ºó¿¬±¸°ú

 

±¹¸³¾Ï¼¾ÅÍ(¿øÀå ¼­È«°ü)´Â ÃÖ±Ù ¼­¿ï·Ôµ¥È£ÅÚ¿¡¼­ °³ÃÖµÈ ¡®Á¦2ȸ ¾Æ½Ã¾ÆÁ¾¾çÇÐȸ ±¹Á¦Çмú´ëȸ(AOS 2022) ¹× Á¦48Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ¡¯¿¡¼­ ±¹¸³¾Ï¼¾ÅÍ ÀÇ·áÁø°ú ¿¬±¸ÁøÀÌ ÃÑ 6°³ÀÇ Çмú»óÀ» µ¿½Ã ¼ö»óÇß´Ù°í ¹àÇû´Ù. 

 

°ø¼±¿µ Áø´Ü°Ë»çÀÇÇаú Àü¹®ÀÇ´Â ¡®Cancer Research and Treatment¡¯ÀÇ ³í¹® ½É»çÀ§¿øÀ¸·Î Ȱµ¿ÇÏ¸ç °´°üÀûÀ̰í Ÿ´çÇÑ ½É»çÀǰßÀ¸·Î ³í¹®ÀÇ ÁúÀû Çâ»ó°ú ¾ÏÇÐȸÁö ¹ßÀü¿¡ ±â¿©ÇÑ °ø·Î¸¦ ÀÎÁ¤¹Þ¾Æ Á¦14ȸ ´ëÇѾÏÇÐȸÁö Best Reviewer»óÀ» ¼ö»óÇß´Ù. ÀÌ¿µÁÖ Æó¾Ï¼¾ÅÍ Ç÷¾×Á¾¾ç³»°ú Àü¹®ÀÇ´Â ¡®Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis¡¯·Î ¡®Á¦12ȸ ´ëÇѾÏÇÐȸ ¸ÓÅ© ¾ÏÇмú»ó¡¯À», ¡®Patient-derived cells (PDCs) recapitulate tumor heterogeneity (TH) to target therapy in advanced lung cancer patients¡¯·Î AOS 2022ÀÇ Best Oral Presentation Award¸¦ ¼ö»óÇØ 2°³ÀÇ »óÀ» ¼ö»óÇÏ´Â ¿µ¿¹¸¦ ¾È¾Ò´Ù.

 

¼­¹Î¾Æ ¾Ï°ËÁø»ç¾÷ºÎÀåÀº ¡®Trends in Cancer Screening Rates among Korean Men and Women: Results of the Korean National Cancer Screening Survey, 2004-2018¡¯ ³í¹®À¸·Î ´ëÇѾÏÇÐȸ ¿ì¼ö³í¹®»óÀ» ¼ö»óÇß´Ù. 

 

¶ÇÇÑ, À¯¿¹ºó Ç¥ÀûÄ¡·á¿¬±¸°ú ¿¬±¸¿øÀº ¡®Established patient-derived organoids using ascites fluid or pleural effusion in cancer patients¡¯·Î AOS 2022ÀÇ Best Oral Presentation Award¸¦, À¯³²Èñ »ý¹°Á¤º¸¿¬±¸°ú ¿¬±¸¿øÀº ¡®Identification of resistance mechanisms and new treatments for advanced lung cancer based on patient-derived cell¡¯·Î Best Poster Presentation Award¸¦ °¢°¢ ¼ö»óÇß´Ù. 

 
 
Copyright¨Ï»çÀ̾𽺿¥µð´º½º ¹«´Ü ÀüÀç ¹× Àç¹èÆ÷ ±ÝÁö
   
 
 
 
 
³×ƼÁð Àǰß(0)
³»¿ë ¾ÆÀ̵ð ÀÛ¼ºÀÏ
 
ÀǰßÀÛ¼ºÇϱâ
 
 
À̸§ ºñ¹Ð¹øÈ£
 
°í·Á´ë »êÇÐÇù·Â´Ü, ¿îµ¿Ã³¹æ ÀΰøÁö´É µ¥ÀÌÅÍ ±¸Ãà»ç¾÷ ¼±Á¤
³úÀüÁõÁö¿ø¼¾ÅÍ, ³úÀüÁõ Å͹̳×ÀÌÅÍ, ·Îº¿ ¼ö¼ú ½Ã´ë ¿­·Á
ÀÇ·á ±â»ç¸ñ·Ï º¸±â
 
Àαⴺ½º
¾Æ½Ã¾Æ ¿ø°ÝÀÇ·áÇÐȸ(ATS) â..
Á¾±Ù´ç, ½Å¾à°³¹ß Àü¹®È¸»ç '..
Åڶ󼼺¤, ID Week¼­ È£ÁÖ 40..
¾ËÇǹÙÀÌ¿À, Äݸ° ´ëüÁ¦ °­È²..
±¤µ¿Á¦¾à, ÀÓÁ÷¿ø Âü¿©Çü Æó°¡..
 
¸¹ÀÌ º» Æ÷Åä´º½º
ÀÇÁ¤ºÎÀ»Áö´ëº´¿ø ¡®Ã£¾Æ°¡´Â ..
ÇÏÀ̷δÐ, ¸¶½ºÅÏ-EDCÞä µî°ú ..
±æ¸®¾îµå, ¿¬¼¼¾Ïº´¿ø°ú Ç×¾Ï..
"¿ì·ç»ç' ´ë¿õ ÀÓÁ÷¿ø Âü¿© '..
 
ÃֽŠÀαⴺ½º
¼­¿ï»ó±ÞÁ¾ÇÕº´¿ø Áö¿ø¸ôµÎ Áß..
»ï¾ç±×·ì, ⸳ 101Áֳ⠡®ÆÛ..
¾ÆÁÖ´ëÀÇ·á¿ø-(ÁÖ)À̹ÙÀÌ¿ÀÁ¨,..
´ëÇÑ¿¹¹æÀÇÇаúÀÇ»çȸ, ⸳ÃÑ..
Ä¡¸Å À¯¹ß ¼ö¸é¹«È£ÈíÁõ, ¡®³ú..